News
Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus ...
Regeneron (REGN) came out with quarterly earnings of $12.89 per share, beating the Zacks Consensus Estimate of $8.03 per ...
StockStory.org on MSN4h
Regeneron’s (NASDAQ:REGN) Q2: Strong SalesBiotech company Regeneron (NASDAQ:REGN) reported in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP ...
During the second quarter of 2025, the Company repurchased shares of its common stock and recorded the cost of the shares, or $1.070 billion, as Treasury Stock. As of June 30, 2025, $2.814 billion ...
Alnylam Pharmaceuticals, Inc. shares soar with strong Q2 results, driven by Amvuttra's stellar U.S. launch for ATTR ...
Q2 2025 Earnings Call Transcript July 31, 2025 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...
22h
Zacks.com on MSNAlnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesThe headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates ...
Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...
Sales of EYLEA HD rose to $393 million from $304 million a year earlier thanks to increased demand. EYLEA sales, meanwhile, declined to $754 million from $1.23 billion, which the company attributed to ...
On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron's Lynozyfic ...
(REGN) on Friday reported second-quarter earnings of $1.39 billion. The Tarrytown, New York-based company said it ...
(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results